Replies to post #522312 on NorthWest Biotherapeutics Inc (NWBO)

[Fireman02360]

None of these questions even matter. You either believe DCVax works and will be approved or it doesn't and wont. These are the ultimate questions that matters. Not whether the compnay "officially" released TLD nor not, or whether the clinicaltrials.gov website was updated or not. We all know the data, as it has been presented at multiple conferences since 5/10. The data speaks for itself. Name another GBM trial with a long-tail and survivor's surpassing 5 years......

"I look forward to the responses"

-Fireman

[JerryCampbell]

Did nwbo release TLD - yes. Doesn't matter who presented it. Company acknowledged it in a PR.

Quiet period - No. Fabricated by apologists as a catch-all excuse for poor nwbo communication.

ASCO - nothing new

Liau was genuinely ill. European covid quarantine restrictions were so strict at the time that it would have been impractical for her to present even if she felt up to it.

I believe .gov endpoints were changed during the week after 5/10. To me, changing to OS as primary is fine as it's a more relevant endpoint than PFS.

If external controls were specified at the start of the trial, that would be fine, but not as a post hoc change. Also note that predictive characteristics are all skewed in nwbo's favor as shown on page 19 of the NYAS presentation.

Recurrent GBM wasn't even part of the original endpoints. Those new endpoints are a post hoc Hail Mary attempt to salvage something from the trial.